Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Leerink Swann increased their Q3 2017 EPS estimates for shares of Gilead Sciences in a research report issued to clients and investors on Thursday. Leerink Swann analyst G. Porges now forecasts that the biopharmaceutical company will post earnings per share of $2.32 for the quarter, up from their prior forecast of $2.26. Leerink Swann has a “Market Perform” rating and a $89.00 price target on the stock.
A number of other equities research analysts have also issued reports on GILD. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Thursday, August 31st. Deutsche Bank AG reissued a “buy” rating and issued a $81.00 price objective on shares of Gilead Sciences in a report on Thursday, August 31st. Credit Suisse Group reissued an “outperform” rating and issued a $85.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a report on Tuesday, August 29th. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 target price on the stock in a research report on Monday, June 26th. Twelve analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $85.66.
WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://ledgergazette.com/2017/10/11/research-analysts-set-expectations-for-gilead-sciences-inc-s-q3-2017-earnings-gild.html.
Shares of Gilead Sciences (NASDAQ GILD) opened at 83.04 on Monday. The stock has a 50 day moving average of $81.55 and a 200-day moving average of $71.93. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27. The stock has a market capitalization of $108.44 billion, a PE ratio of 9.02 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.08 earnings per share.
A number of institutional investors have recently bought and sold shares of the stock. Fulton Bank N.A. increased its position in Gilead Sciences by 5.0% during the 3rd quarter. Fulton Bank N.A. now owns 50,157 shares of the biopharmaceutical company’s stock worth $4,064,000 after purchasing an additional 2,391 shares in the last quarter. Curbstone Financial Management Corp increased its position in Gilead Sciences by 101.6% during the 3rd quarter. Curbstone Financial Management Corp now owns 28,170 shares of the biopharmaceutical company’s stock worth $2,282,000 after purchasing an additional 14,200 shares in the last quarter. Perpetual Ltd grew its holdings in Gilead Sciences by 10.1% in the 2nd quarter. Perpetual Ltd now owns 175,900 shares of the biopharmaceutical company’s stock valued at $12,450,000 after buying an additional 16,100 shares during the period. Intl Fcstone Inc. purchased a new stake in Gilead Sciences in the 2nd quarter valued at about $1,110,000. Finally, Griffin Asset Management Inc. purchased a new stake in Gilead Sciences in the 2nd quarter valued at about $1,151,000. Hedge funds and other institutional investors own 73.98% of the company’s stock.
In related news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the sale, the executive vice president now owns 106,113 shares in the company, valued at approximately $8,051,854.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.56, for a total value of $6,054,372.48. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock valued at $39,298,919 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.